Ni Liu

TL;DR: Among patients with non-small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.

TL;DR: EGFR mutations and high copy number are predictive of response to erlotinib and EGFR FISH is the strongest prognostic marker and a significant predictive marker of differential survival benefit from erlot inib.

TL;DR: This 15-gene expression signature is an independent prognostic marker in early-stage, completely resected NSCLC, and to the authors' knowledge, is the first signature that has demonstrated the potential to select patients with stage IB to IINSCLC most likely to benefit from adjuvant chemotherapy with cisplatin/vinorelbine.

TL;DR: In this paper, the prognostic and predictive value of p53 gene/protein aberrations using tumor samples from JBR.10, a North American phase III intergroup trial that randomly assigned 482 patients with completely resected stage IB and II non-small-cell lung cancer (NSCLC) to receive four cycles of adjuvant cisplatin plus vinorelbine or observation alone.

TL;DR: Results indicate that except for the loss of p53 functional pathway, the two clones of HPDE6-E6E7 cells demonstrated a near normal genotype and phenotype of pancreatic duct epithelial cells, which will be useful for future studies on the molecular basis of pancreas cancerogenesis and islet cell differentiation.